{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:23:14Z","timestamp":1792596194534,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02260-7","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:08:37Z","timestamp":1740967717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Stephen Jun Fei","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Z.","family":"Lehmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Qing","family":"Eu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ren","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"1","key":"2260_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000533704","volume":"147","author":"S Kang","year":"2024","unstructured":"Kang S, Ahn IE. Prognostic Markers in the Era of Targeted Therapies. Acta Haematol. 2024;147(1):33\u201346.","journal-title":"Acta Haematol"},{"issue":"15","key":"2260_CR2","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","volume":"26","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, et al. Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/II PCYC-1102 Study. Clin Cancer Res. 2020;26(15):3918\u201327.","journal-title":"Clin Cancer Res"},{"issue":"10232","key":"2260_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278\u201391.","journal-title":"Lancet"},{"issue":"7354","key":"2260_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101\u20135.","journal-title":"Nature"},{"issue":"7574","key":"2260_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525\u201330.","journal-title":"Nature"},{"issue":"1","key":"2260_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1172\/JCI93801","volume":"128","author":"S Dietrich","year":"2018","unstructured":"Dietrich S, Oles M, Lu J, Sellner L, Anders S, Velten B, et al. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018;128(1):427\u201345.","journal-title":"J Clin Invest"},{"key":"2260_CR7","doi-asserted-by":"crossref","unstructured":"Lukas M, Velten B, Sellner L, Tomska K, Huellein J, Walther T, et al. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia. 2020.","DOI":"10.1038\/s41375-020-0846-5"},{"issue":"2","key":"2260_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, et al. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 2022;12(2):372\u201387.","journal-title":"Cancer Discov"},{"issue":"1","key":"2260_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"MV Del Gaizo","year":"2007","unstructured":"Del Gaizo MV, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112\u201321.","journal-title":"J Clin Invest"},{"issue":"25","key":"2260_CR10","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215\u201324.","journal-title":"Blood"},{"issue":"6","key":"2260_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2260_CR12","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31(10):2075\u201384.","journal-title":"Leukemia"},{"key":"2260_CR13","doi-asserted-by":"crossref","unstructured":"Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, et al. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. 2023;133(22).","DOI":"10.1172\/JCI170169"},{"issue":"8","key":"2260_CR14","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","volume":"6","author":"MS Davids","year":"2019","unstructured":"Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6(8):e419\u201328.","journal-title":"Lancet Haematol"},{"key":"2260_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","volume":"1877","author":"C Fraser","year":"2019","unstructured":"Fraser C, Ryan J, Sarosiek K. BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies. Methods Mol Biol. 2019;1877:61\u201376.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2260_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"MV Del Gaizo","year":"2013","unstructured":"Del Gaizo MV, Letai A. BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332(2):202\u20135.","journal-title":"Cancer Lett"},{"issue":"12","key":"2260_CR17","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ajh.24808","volume":"92","author":"J Crombie","year":"2017","unstructured":"Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92(12):1393\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"2260_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48(3):253\u201364.","journal-title":"Nat Genet"},{"issue":"8","key":"2260_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","volume":"2","author":"J Lu","year":"2021","unstructured":"Lu J, Cannizzaro E, Meier-Abt F, Scheinost S, Bruch PM, Giles HA, et al. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nat Cancer. 2021;2(8):853\u201364.","journal-title":"Nat Cancer"},{"issue":"2","key":"2260_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521\u20139.","journal-title":"Blood"},{"key":"2260_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fonc.2018.00229","volume":"8","author":"E Rosati","year":"2018","unstructured":"Rosati E, Baldoni S, De Falco F, Del Papa B, Dorillo E, Rompietti C, et al. NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. Front Oncol. 2018;8:229.","journal-title":"Front Oncol"},{"issue":"21","key":"2260_CR22","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247\u201354.","journal-title":"Blood"},{"issue":"12","key":"2260_CR23","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3324\/haematol.2018.190132","volume":"103","author":"LV Abruzzo","year":"2018","unstructured":"Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, et al. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica. 2018;103(12):2069\u201378.","journal-title":"Haematologica"},{"issue":"26","key":"2260_CR24","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910\u20136.","journal-title":"N Engl J Med"},{"issue":"8","key":"2260_CR25","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41418-020-0503-6","volume":"27","author":"MD Haschka","year":"2020","unstructured":"Haschka MD, Karbon G, Soratroi C, O\u2019Neill KL, Luo X, Villunger A. MARCH5-dependent degradation of MCL1\/NOXA complexes defines susceptibility to antimitotic drug treatment. Cell Death Differ. 2020;27(8):2297\u2013312.","journal-title":"Cell Death Differ"},{"key":"2260_CR26","doi-asserted-by":"crossref","unstructured":"Chiou JT, Huang NC, Huang CH, Wang LJ, Lee YC, Shi YJ, Chang LS. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. J Cell Physiol. 2021;236(11):7356\u2013575.","DOI":"10.1002\/jcp.30407"},{"key":"2260_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13148-017-0356-0","volume":"9","author":"L Rani","year":"2017","unstructured":"Rani L, Mathur N, Gupta R, Gogia A, Kaur G, Dhanjal JK, et al. Genome-wide DNA methylation profiling integrated with gene expression profiling identifies PAX9 as a novel prognostic marker in chronic lymphocytic leukemia. Clin Epigenetics. 2017;9:57.","journal-title":"Clin Epigenetics"},{"issue":"16","key":"2260_CR28","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1074\/jbc.RA117.000972","volume":"293","author":"Y Du","year":"2018","unstructured":"Du Y, Liu Y, Xu Y, Juan J, Zhang Z, Xu Z, et al. The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. J Biol Chem. 2018;293(16):5847\u201359.","journal-title":"J Biol Chem"},{"issue":"15","key":"2260_CR29","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.devcel.2021.06.010","volume":"56","author":"RB Shah","year":"2021","unstructured":"Shah RB, Kernan JL, van Hoogstraten A, Ando K, Li Y, Belcher AL, et al. FANCI functions as a repair\/apoptosis switch in response to DNA crosslinks. Dev Cell. 2021;56(15):2207\u201322.e7.","journal-title":"Dev Cell"},{"key":"2260_CR30","doi-asserted-by":"publisher","unstructured":"Shukla A, Chaturvedi NK, Ahrens AK, Cutucache CE, Mittal AK, Bierman P, et al. Stromal tumor microenvironment in chronic lymphocytic leukemia: regulation of leukemic progression. J Leuk. 2013;1(2):113. https:\/\/doi.org\/10.4172\/2329-6917.1000113.","DOI":"10.4172\/2329-6917.1000113"},{"issue":"22","key":"2260_CR31","doi-asserted-by":"publisher","first-page":"12727","DOI":"10.1093\/nar\/gkaa1110","volume":"48","author":"SJF Chong","year":"2020","unstructured":"Chong SJF, Iskandar K, Lai JXH, Qu J, Raman D, Valentin R, et al. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020;48(22):12727\u201345.","journal-title":"Nucleic Acids Res"},{"key":"2260_CR32","doi-asserted-by":"crossref","unstructured":"Kotaskova J, Tichy B, Trbusek M, Francova HS, Kabathova J, Malcikova J, et al. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn. 2010;12(3):328\u201334.","DOI":"10.2353\/jmoldx.2010.090100"},{"issue":"3","key":"2260_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/cdd.2009.132","volume":"17","author":"ZX Chen","year":"2010","unstructured":"Chen ZX, Pervaiz S. Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ. 2010;17(3):408\u201320.","journal-title":"Cell Death Differ"},{"issue":"16","key":"2260_CR34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1089\/ars.2017.7441","volume":"29","author":"SJF Chong","year":"2018","unstructured":"Chong SJF, Lai JXH, Eu JQ, Bellot GL, Pervaiz S. Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison. Antioxid Redox Signal. 2018;29(16):1553\u201388.","journal-title":"Antioxid Redox Signal"},{"key":"2260_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2019.05.009","volume":"457","author":"SJF Chong","year":"2019","unstructured":"Chong SJF, Lai JXH, Qu J, Hirpara J, Kang J, Swaminathan K, et al. A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression. Cancer Lett. 2019;457:151\u201367.","journal-title":"Cancer Lett"},{"issue":"4","key":"2260_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019;36(4):369\u201384.e13.","journal-title":"Cancer Cell"},{"issue":"8","key":"2260_CR37","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1111\/jcmm.15105","volume":"24","author":"KY Song","year":"2020","unstructured":"Song KY, Zhang XZ, Li F, Ji QR. Silencing of ATP2B1-AS1 contributes to protection against myocardial infarction in mouse via blocking NFKBIA-mediated NF-\u03baB signalling pathway. J Cell Mol Med. 2020;24(8):4466\u201379.","journal-title":"J Cell Mol Med"},{"key":"2260_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.720468","volume":"9","author":"L Wang","year":"2021","unstructured":"Wang L, Tan Y, Zhu Z, Chen J, Sun Q, Ai Z, et al. ATP2B1-AS1 Promotes Cerebral Ischemia\/Reperfusion Injury Through Regulating the miR-330-5p\/TLR4-MyD88-NF-\u03baB Signaling Pathway. Front Cell Dev Biol. 2021;9: 720468.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"2260_CR39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","volume":"36","author":"EM Ghia","year":"2022","unstructured":"Ghia EM, Rassenti LZ, Choi MY, Quijada-\u00c1lamo M, Chu E, Widhopf GF 2nd, Kipps TJ. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. Leukemia. 2022;36(6):1609\u201318.","journal-title":"Leukemia"},{"key":"2260_CR40","doi-asserted-by":"crossref","unstructured":"Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, et al. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Front Immunol. 2020;11:608167.","DOI":"10.3389\/fimmu.2020.608167"},{"issue":"14","key":"2260_CR41","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1182\/blood-2014-03-563296","volume":"124","author":"IC Low","year":"2014","unstructured":"Low IC, Loh T, Huang Y, Virshup DM, Pervaiz S. Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56delta stabilizes its antiapoptotic activity. Blood. 2014;124(14):2223\u201334.","journal-title":"Blood"},{"issue":"11","key":"2260_CR42","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/1078-0432.CCR-20-3913","volume":"27","author":"DF Boreel","year":"2021","unstructured":"Boreel DF, Span PN, Heskamp S, Adema GJ, Bussink J. Targeting Oxidative Phosphorylation to Increase the Efficacy of Radio- and Immune-Combination Therapy. Clin Cancer Res. 2021;27(11):2970\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2260_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/bloodadvances.2023011574","volume":"8","author":"IE Ahn","year":"2024","unstructured":"Ahn IE, Brander DM, Ren Y, Zhou Y, Tyekucheva S, Walker HA, et al. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood Adv. 2024;8(4):832\u201341.","journal-title":"Blood Adv"},{"issue":"1","key":"2260_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):67.","journal-title":"J Hematol Oncol"},{"key":"2260_CR45","doi-asserted-by":"crossref","unstructured":"Mazumder S, Choudhary GS, Al-Harbi S and Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72(12):3069\u201379.","DOI":"10.1158\/0008-5472.CAN-11-4106"},{"issue":"11","key":"2260_CR46","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19(11):1294\u2013305.","journal-title":"Genes & Development"},{"issue":"47","key":"2260_CR47","doi-asserted-by":"publisher","first-page":"12034","DOI":"10.1073\/pnas.1806928115","volume":"115","author":"Y Liu","year":"2018","unstructured":"Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci U S A. 2018;115(47):12034\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2260_CR48","first-page":"53","volume":"1766","author":"SK Radhakrishnan","year":"2006","unstructured":"Radhakrishnan SK, Kamalakaran S. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim Biophys Acta. 2006;1766(1):53\u201362.","journal-title":"Biochim Biophys Acta"},{"issue":"28","key":"2260_CR49","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1038\/sj.onc.1205536","volume":"21","author":"D Bernard","year":"2002","unstructured":"Bernard D, Monte D, Vandenbunder B, Abbadie C. The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD. Oncogene. 2002;21(28):4392\u2013402.","journal-title":"Oncogene"},{"issue":"50","key":"2260_CR50","doi-asserted-by":"publisher","first-page":"12896","DOI":"10.1523\/JNEUROSCI.3670-06.2006","volume":"26","author":"I Inta","year":"2006","unstructured":"Inta I, Paxian S, Maegele I, Zhang W, Pizzi M, Spano P, et al. Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J Neurosci. 2006;26(50):12896\u2013903.","journal-title":"J Neurosci"},{"issue":"3","key":"2260_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.18632\/aging.100026","volume":"1","author":"AG Martin","year":"2009","unstructured":"Martin AG, Trama J, Crighton D, Ryan KM, Fearnhead HO. Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B. Aging (Albany NY). 2009;1(3):335\u201349.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"2260_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/intimm\/7.4.533","volume":"7","author":"L Genestier","year":"1995","unstructured":"Genestier L, Bonnefoy-Berard N, Rouault JP, Flacher M, Revillard JP. Tumor necrosis factor-alpha up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines. Int Immunol. 1995;7(4):533\u201340.","journal-title":"Int Immunol"},{"issue":"50","key":"2260_CR53","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","volume":"20","author":"SD Catz","year":"2001","unstructured":"Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001;20(50):7342\u201351.","journal-title":"Oncogene"},{"issue":"5","key":"2260_CR54","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.cmet.2017.10.013","volume":"26","author":"C Bosc","year":"2017","unstructured":"Bosc C, Selak MA, Sarry JE. Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment. Cell Metab. 2017;26(5):705\u20137.","journal-title":"Cell Metab"},{"issue":"2","key":"2260_CR55","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1172\/JCI65093","volume":"124","author":"A Gutierrez","year":"2014","unstructured":"Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest. 2014;124(2):644\u201355.","journal-title":"J Clin Invest"},{"key":"2260_CR56","doi-asserted-by":"crossref","unstructured":"Sonkar VK, Eustes AS, Ahmed A, Jensen M, Solanki MV, Swamy J, et al. Endogenous SOD2 (Superoxide Dismutase) Regulates Platelet-Dependent Thrombin Generation and Thrombosis During Aging. Arterioscler Thromb Vasc Biol. 2023;43(1):79\u201391.","DOI":"10.1161\/ATVBAHA.121.317735"},{"issue":"8","key":"2260_CR57","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2326-6066.CIR-19-0880","volume":"8","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Haug A, J\u00e4ger U, Pichler V, Pfaff S, Wester HJ, et al. In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Cancer Immunol Res. 2020;8(8):984\u20139.","journal-title":"Cancer Immunol Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:43:40Z","timestamp":1741009420000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2260"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02260-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent has been obtained from patients and approval have been granted by the Ethics Committee Heidelberg (University of Heidelberg, Germany; S-206\/2011;S-356\/2013) and Dana-Farber\/Harvard Cancer Center Institutional Review Board; #99-224).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"RV is a current employee of Genmab Biotechnology Company, Copenhagen, Denmark. TZL is a current employee at Casma Therapeutics, Inc, Cambridge, MA, USA. CH has received honoraria from AbbVie, Janssen, Roche, Gilead, Takeda, Daiichi and personal fees from AbbVie, Janssen, Roche, Gilead, Takeda. BCG consults and serves on the Advisory board for MSD, Merck KGaA, Novartis, Adagene Inc., Bayer Healthcare and receives research funding from Taiho pharmaceuticals, Otsuka pharmaceuticals, Adagene Inc., Bayer Healthcare, Alx Oncology, Sanofi and Amgen. JRB has served as a consultant for Abbvie, Acerta\/Astra-Zeneca, BeiGene, Genentech\/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, Kite, Loxo\/Lilly, MEI Pharma, Numab Therapeutics, Pfizer, Pharmacyclics and received research funding from BeiGene, Gilead, iOnctura, Loxo\/Lilly, MEI Pharma, TG Therapeutics. CUN has received consultancy fees and\/or travel grants from Janssen, Abbvie, Novartis, Roche, Sunesis, Gilead, AstraZeneca, and CSL Behring, research support from Abbvie, AstraZeneca, Janssen and Novo Nordisk Foundation (NNF16OC0019302). TZ has received honoraria from Roche, Abbvie, Gilead, Janssen, AstraZeneca, Eli Lilly and Janpix. MSD has received institutional research funding from Ascentage Pharma, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics and personal consulting income from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals, Secura Bio, TG Therapeutics, and Takeda. Other authors have no potential conflicts of interest or relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}